Definium Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
DFTX$34.64-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders' Equity
| Common Shares | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands, except share amounts) · Shares · Amount · Additional Paid-In Capital · Accumulated OCI · Accumulated Deficit · Total | ||||||||||
| Balance, December 31, 2025 | 98,776,265 | $— | $913,914 | $1,085 | $(582,672) | $332,327 | ||||
| Issuance of common shares under employee share purchase plan ("ESPP") | 33,787 | — | 276 | — | — | 276 | ||||
| Issuance of common shares upon settlement of restricted share unit ("RSU") awards | 169,306 | — | — | — | — | — | ||||
| Exercise of 2022 USD Financing Warrants | 901,800 | — | 15,313 | — | — | 15,313 | ||||
| Exercise of pre-funded warrants | 4,000,000 | 4 | — | — | 4 | |||||
| Amortization of deferred ATM costs | — | — | (40) | — | — | (40) | ||||
| Stock-based compensation expense | — | — | 7,132 | — | — | 7,132 | ||||
| Exercise of stock options | 163,350 | — | 1,196 | — | — | 1,196 | ||||
| Net loss and comprehensive loss | — | — | — | (261) | (77,098) | (77,359) | ||||
| Balance, March 31, 2026 | 104,044,508 | $— | $937,795 | $824 | $(659,770) | $278,849 | ||||
| Issuance of common shares, net of shares issuance cost | 23,676,471 | — | 758,730 | — | — | 758,730 | ||||
| Issuance of common shares upon conversion of term loan principal | 594,016 | — | 4,500 | — | — | 4,500 | ||||
| Issuance of common shares upon settlement of RSU awards | 293,055 | — | — | — | — | — | ||||
| Exercise of 2022 USD Financing Warrants | 669,895 | — | 25,532 | — | — | 25,532 | ||||
| Exercise of pre-funded warrants | 5,018,775 | — | 5 | — | — | 5 | ||||
| Amortization of deferred ATM costs | — | — | (42) | — | — | (42) | ||||
| Stock-based compensation expense | — | — | 9,639 | — | — | 9,639 | ||||
| Exercise of stock options | 69,230 | — | 859 | — | — | 859 | ||||
| Net loss and comprehensive loss | — | — | — | (407) | (158,986) | (159,393) | ||||
| Balance, June 30, 2026 | 134,365,950 | $— | $1,737,018 | $417 | $(818,756) | $918,679 | ||||
| Balance, December 31, 2024 | 75,100,763 | $— | $639,508 | $819 | $(398,879) | $241,448 | ||||
| Issuance of common shares under ESPP | 34,017 | — | 186 | — | — | 186 | ||||
| Issuance of common shares upon settlement of RSU awards | 186,708 | — | — | — | — | — | ||||
| Exercise of 2022 USD Financing Warrants | 136,346 | — | 874 | — | — | 874 | ||||
| Stock-based compensation expense | — | — | 3,426 | — | — | 3,426 | ||||
| Exercise of stock options | 53,541 | — | 237 | — | — | 237 | ||||
| Net loss and comprehensive loss | — | — | — | (17) | (23,348) | (23,365) | ||||
| Balance, March 31, 2025 | 75,511,375 | $— | $644,231 | $802 | $(422,227) | $222,806 | ||||
| Issuance of common shares upon settlement of RSU awards | 229,587 | — | — | — | — | — | ||||
| Stock-based compensation expense | — | — | 5,253 | — | — | 5,253 | ||||
| Exercise of stock options, net of shares withheld for exercise and tax | 62,289 | — | 80 | — | — | 80 | ||||
| Net loss and comprehensive loss | — | — | — | 5 | (42,744) | (42,739) | ||||
| Balance, June 30, 2025 | 75,803,251 | $— | $649,564 | $807 | $(464,971) | $185,400 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.